Sometimes the smartest answer isn’t the most technical one. This collection highlights ingenious fixes that cut through ...

Berkshire Hathaway provides an "anchor" to a portfolio with its massive war chest of cash. Apple's business is seeing accelerating momentum. These two stocks give investors access to both cutting-edge ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

Sam Altman and Jony Ive have moved their screenless, pocketable AI hardware from concept to prototype, expecting a debut in less than two years The “third core device” is designed around ambient ...

Now that the holidays are here, it’s time to start planning your upcoming family feasts — including what beer you’re going to serve. Over the years, I’ve offered advice on tasty ways to pair beer with ...

Covering the video games industry since 2017, with experience in news, articles, lists, and reviews (and I blame The Legend of Zelda: Majora's Mask for that). If you are a fan of RPGs and want a third ...

A lawyer for the former F.B.I. director said he would accuse the Justice Department of malicious and selective prosecution and contend that a U.S. attorney was illegally appointed. By Charlie Savage ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

When Gene Roddenberry created "Star Trek," he didn't pull it out of a vacuum. Impressed with a real life World War II Navy vessel, the USS Enterprise, Roddenberry modeled the capital ship of Starfleet ...

The Grammys and the Latin Grammys have a lot in common. The four highest-profile awards are the same at both shows – album, record and song of the year plus best new artist. Both shows also present ...

Vanguard Extended Market ETF VXF tracks a total market index that excludes S&P 500 stocks. It’s a misfit in the mid-cap blend category, but it pairs well with a fund that tracks the S&P 500 index to ...